LECARNITA is injectable levocarnitine

Active ingredient: levocarnitine

Levocarnitine — a natural substance necessary for energy metabolism. Levokarnitin facilitates the intake of long-chain fatty acids in the mitochondria of cells, thus providing a substrate for oxidation and energy production. Fatty acids are used as a substrate for the formation of energy and in all tissues, except the brain. The primary systemic deficiency of carnitine is characterized by a low concentration of levocarnitine in the blood plasma, erythrocytes and / or tissues. It is not known exactly which symptoms are caused by a deficiency of carnitine, and which are due to organic acidemia, as it is expected that carnitine can alleviate the symptoms of both pathologies. Carnitine improves the removal of excess organic and fatty acids in patients with impaired metabolism of fatty acids and / or with specific organic acidopathies that cause accumulation in the body of acyl-CoA

Secondary insufficiency arises in connection with the alimentary deficiency of carnitine, its incomplete synthesis in the body or at exceptionally high endogenous requirements of the organism in carnitine, including in seriously ill patients, weakened patients and patients in the postoperative period. A significant reduction in the level of carnitine in the myocardium is determined in patients with dilated cardiomyopathy and ischemic heart disease. The total carnitine level in the myocardium decreased to 42% with heart failure. It was proved that the deficiency of carnitine causes a decrease in the contractility of the myocardium, a violation of the heart rhythm

Carnitine deficiency may be due to congenital metabolic disorders. Carnitine may reduce metabolic disorders in patients with congenital abnormalities that cause accumulation of toxic organic acids. This effect was demonstrated for the following conditions: glutaric aciduria II, methylmalonic aciduria, propionic acidemia, and acyl-CoA dehydrogenase deficiency in medium chain fatty acids. Auto-toxication in such patients arises as a result of the accumulation of reports of acyl-CoA that disrupt the intermediate metabolism. Further hydrolysis of compounds of acyl-CoA to the free acid causes acidosis, which can be life threatening. Levokarnitin neutralizes the acyl-CoA compounds, forming acylcarnitine, which is rapidly excreted from the body. Carnitine is effective for alcoholic, medicinal intoxication, as well as for intoxication caused by xenobiotics. The insufficiency of carnitine is revealed by the biochemical method of the ultra low concentration of free carnitine in the blood plasma (0.4 or abnormally high concentrations of acylcarnitine in the urine.In preterm infants and newborns, secondary insufficiency manifests as a concentration of levocarnitine in the blood plasma below the age dose.Carnitine efficacy in peripheral neuropathy, Including diabetic and alcoholic, in patients with obesity and atherogenic dyslipidemia. Levocarnitin increases the sensitivity of cells current to the action of insulin

  • LECARNITA replenishes energy deficiency, improves heart function and normalizes metabolic processes
  • LECARNITA reduces the manifestations of heart failure, positively affects the activity of the central nervous system
  • LECARNITA improves energy metabolism, reduces fatty liver infiltration, has antitoxic properties
  • Primary (congenital) insufficiency of carnitine
  • Secondary insufficency of carnitine
  • Cardiomyopathy

Doses and duration of treatment are set individually, depending on the age and nosological form of the disease. Rp for injection is administered by slow intravenous injection (2-3 minutes) or infusion
Primary carnitine insufficiency: in cases of acute metabolic disorders, the drug is administered IV in a dose of 50-100 mg / kg body weight daily in 3-4 divided doses. If necessary, it can be used in higher doses, although side effects may increase, primarily diarrhea
Secondary carnitine insufficiency: in secondary carnitine deficiency, the drug is used at a dose of 10-20 mg/kg body weight by iv bolus injection at the end of each hemodialysis procedure (with three procedures for a week). The duration of IV application should be at least 3 months - this time is usually necessary to restore the normal level of free carnitine in the muscles. The overall response should be assessed based on the patient's condition and the results of repeated monitoring of carnitine levels in the blood plasma
Haemodialysis: maintenance dose. If the clinical effect is obtained by intravenous administration, it can be maintained daily by taking 1 g of L-carnitine orally. On dialysis day, levokarnitin oral should be used at the end of the procedure

With prolonged use of L-carnitine, various minor abnormalities from the digestive tract were reported: nausea and vomiting, flatulence, diarrhea. Only with the use of L-carnitine in patients with uremia described cases of mild myasthenia
Sensitivity to the drug should be carefully evaluated during the first week of the drug and after each dose increase
Cases of convulsive seizures are described in patients with both existing convulsive activity and without it, who received levocarnitine orally or IV

Avoid using in case of known hypersensitivity to one or more components of the product

Administration of levocarnitine to patients with diabetes mellitus receiving insulin or oral hypoglycemic agents can cause hypoglycemia. Such patients require constant monitoring of blood glucose levels to correct the regimen of hypoglycemic treatment. In / in the introduction of L-carnitine should be done slowly (2-3 min). Long-term use of the drug without the addition of potassium can cause hypokalemia, therefore, it is necessary to control the electrolyte balance when using the drug. Long-term oral administration of levocarnitine in high doses in patients with severe forms of renal dysfunction or end-stage renal failure is not recommended, as this can lead to the accumulation of potentially toxic metabolites, trimethylamine (TMA) trimethylamine-N-oxide, through inadequate kidney secretion. This accumulation leads to an increase in TMA in urine
Do not exceed the recommended dose of the drug. If any side effects occur, the drug should be discarded
Use during pregnancy and lactation: teratogenic and embryotoxic effects of the drug are not documented, but in view of the lack of adequate controlled clinical trials, the use of the drug in pregnant women is possible only if the expected benefit for the mother exceeds the possible risk to the fetus. If it is necessary to use the drug during lactation, breast-feeding should be stopped for the period of treatment with the drug
Children: the drug is prescribed to children from the first day of life, including premature
The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Not affected. Simultaneous application of GCS leads to the accumulation of levocarnitine in the tissues of the body (except for the liver). Other anabolic agents increase the effect of the drug
Incompatibility: do not mix with other medicines
Overdosing: data of toxicity of Levocarnitine in an overdose have not been reported. The use of the drug in high doses can cause diarrhea. Levokarnitin is easily removed from the plasma by dialysis. In case of an overdose, symptomatic treatment is performed

Store in a dark place at a temperature not above 25 °C. Keep out of the reach of children!

Solution for injection in ampoules, 5 ml

By prescription